Skip Navigation Links

Project Information

THERAPEUTIC ROLE OF BMI-1 INHIBITORS IN ELIMINATING PROSTATE TUMOR STEM CELLS

Agency:
CDMRP

DOD/Congressionally Directed Medical Research Programs

Project Number:
PC111595
Contact PI / Project Leader:
SABAAWY, HATEM
Awardee Organization:
RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK

Description

Abstract Text:
Background: Prostate tumor-initiating cells (TICs) have the exclusive abilities to self-renew and to initiate tumors in immune-deficient recipients. Prostate TICs survive treatment due to their intrinsic resistance to current therapies. Elevated expression of Bmi-1 (B-cell specific MMLV insertion site) occurs in prostate tumor stem cells. Bmi-1 promotes tumorigenesis by repressing genes regulating cell cycle and apoptosis and by suppressing growth inhibitor proteins. Thus, Bmi-1 is an ideal drug target to eliminate self-renewal of prostate TICs. Pressing questions are whether Bmi-1 inhibitors are effective against prostate cancer and if combining Bmi-1 inhibitors with chemotherapy causes tumor eradication. Objective/Hypothesis: Our goal is to identify and subsequently develop a new class of bioavailable small molecules that inhibit tumor growth by selectively reducing Bmi-1 production. In preliminary studies, we found Bmi-1 to be overexpressed in 44% of advanced prostate tumors. We hypothesize that Bmi-1 plays a vital role in prostate TIC maintenance and that drugs targeting Bmi-1 will eliminate TICs in patient tumors. We have identified three potent and selective compounds that reduce Bmi-1 expression in prostate cancer cell lines in vitro and in vivo. We propose to use mice and zebrafish xenografts of primary cells to (1) select a compound(s) that potently, selectively, and safely reduce Bmi-1 expression in primary prostate TICs and (2) develop a clinical strategy for combination therapy. Specific Aims: (1) Determine the extent of aberrant expression of Bmi-1 in primary prostate tumors and study of the role of Bmi-1 in regulating prostate TIC self-renewal. (a) Analyses of Bmi-1 expression in primary and metastatic prostate cancer patients. (b) Study of the effects of Bmi-1 knockdown on putative TICs in vitro and in vivo with serially engrafted zebrafish and mice xenografts. (2) Evaluate the therapeutic response to combining small molecule Bmi-1 inhibitors with chemotherapy to eradicate prostate TIC xenografts. We have identified three Bmi-1 inhibitors with antitumor activity at ED50 of <1mM. We will study the additive or synergetic effects of combining Bmi-1 inhibitors, to target self-renewal in primary prostate TICs, with cisplatin and taxanes that can debulk tumors in order to reach total tumor eradication. Study Design: TICs isolated by phenotypic and time-of-adherence assays from fresh tumors and DU145 cells will be used to generate zebrafish xenografts. The tumor initiation potential will be confirmed in established mouse xenografts. The effect of Bmi-1 inhibitors against primary xenografts generated in zebrafish and mice will be investigated as monotherapy and in combination with cisplatin and taxotere. These studies will allow us to (1) identify a Bmi-1 inhibitor(s) with in vivo potency, selectivity, and antitumor activity in animal models and (2) develop a clinical strategy for combination therapy. Synergy: This proposal utilizes the expertise of three laboratories: the Sabaawy laboratory, with expertise in using zebrafish as a vertebrate model to study carcinogenesis and drug effects; the Bertino laboratory, with experience in cell biology and molecular pharmacology; and the Kim laboratory, with experience in prostate cancer biology and mouse xenografts, together with the availability of Bmi-1 inhibitors from PTC Therapeutics, and the clinical prostate cancer translation team at the Gallo Prostate Cancer Center. Innovation: There are two novel and potentially broad-reaching concepts in this proposal. First, zebrafish provide an ideal vertebrate for prostate cancer xenografts. Second, we will escalate the development of novel Bmi-1 inhibitor(s) that target TICs in prostate cancer for clinical trials. Impact: Bmi-1 inhibitors that target prostate cancer TICs may provide a new class of inhibitors that when used alone and in combination would be effective therapies for many patients with prostate cancer. Focus Area: This proposal is focused in the areas of therapeutics and prostate tumor biology.
Project Terms:
Animal Model; Apoptosis; Area; Bioavailable; Biological Assay; B-Lymphocytes; Cancer Biology; Cancer Center; Cancer Patient; Cell Cycle; Cell Maintenance; Cells; Cellular biology; chemotherapy; Cisplatin; Clinical; Clinical Trials; Combined Modality Therapy; Development; docetaxel; drug carcinogenesis; Drug Delivery Systems; DU145; effective therapy; experience; Genes; Goals; Growth Inhibitors; Immune; In Vitro; in vivo; inhibitor/antagonist; innovation; Laboratories; Malignant neoplasm of prostate; Metastatic Prostate Cancer; Modeling; Molecular; Mus; novel; overexpression; Patients; PC3 cell line; Pharmacology; Play; Production; Prostatic Neoplasms; Proteins; Research Design; Resistance; response; Role; self-renewal; Site; small molecule; taxane; Taxane Compound; Therapeutic; Time; Translations; tumor; Tumor Biology; Tumor Debulking; tumor eradication; tumor growth; tumor initiation; Tumor Stem Cells; tumorigenesis; Xenograft procedure; Zebrafish

Details

Contact PI / Project Leader Information:
Name:  SABAAWY, HATEM
Other PI Information:
Not Applicable
Awardee Organization:
Name:  RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK
City:  NEW BRUNSWICK    
Country:  UNITED STATES
Congressional District:
State Code:  NJ
District:  06
Other Information:
Fiscal Year: 2011
Award Notice Date:
DUNS Number: 001912864
Project Start Date: 30-Sep-2012
Budget Start Date:
CFDA Code: 12.420
Project End Date: 29-Sep-2015
Budget End Date:
Agency: ?

Agency: The entity responsible for the administering of a research grant, project, or contract. This may represent a federal department, agency, or sub-agency (institute or center). Details on agencies in Federal RePORTER can be found in the FAQ page.

DOD/Congressionally Directed Medical Research Programs
Project Funding Information for 2011:
Year Agency

Agency: The entity responsible for the administering of a research grant, project, or contract. This may represent a federal department, agency, or sub-agency (institute or center). Details on agencies in Federal RePORTER can be found in the FAQ page.

FY Total Cost
2011 CDMRP

DOD/Congressionally Directed Medical Research Programs

$585,000

Results

i

It is important to recognize, and consider in any interpretation of Federal RePORTER data, that the publication and patent information cannot be associated with any particular year of a research project. The lag between research being conducted and the availability of its results in a publication or patent award varies substantially. For that reason, it's difficult, if not impossible, to associate a publication or patent with any specific year of the project. Likewise, it is not possible to associate a publication or patent with any particular supplement to a research project or a particular subproject of a multi-project grant.

ABOUT FEDERAL REPORTER RESULTS

Publications: i

Click on the column header to sort the results

PubMed = PubMed PubMed Central = PubMed Central Google Scholar = Google Scholar

Patents: i

Click on the column header to sort the results

Similar Projects

Download Adobe Acrobat Reader:Adobe Acrobat VERSION: 3.41.0 Release Notes
Back to Top